Slide 1: Phase 3 VERITAC-2 Trial Results
PHASE 3 VERITAC-2 TRIAL RESULTS NASDAQ L I S T E D ARVN June 2, 2025 © 2025 Arvinas. All rights reserved. 1
Slide 2: Safe harbor and forward-looking statements
Safe harbor and forward-looking statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding vepdegestrant's potential to be a best-in-class
Slide 3: Igniting a transformative change
IGNITING A TRANSFORMATIVE CHANGE in the fight for patients with cancer and neurodegenerative diseases
Slide 4: PROTAC degraders harness the body's natural machinery to degrade disease-causing proteins
PROTAC degraders harness the body’s natural machinery to degrade, not simply inhibit, disease-causing proteins E3 ligase PROTEIN TAGGING: 2 Tagging of target protein COMPLEX FORMATION: for degradation 1 Target Protein Recognizing disease Ubiquitin causing protein of interest ITERATIVE ACTIVITY PROTE
Slide 5: Tumors develop common resistance mutations that do not utilize the ER pathway
Tumors develop common resistance mutations that do not utilize the ER pathway for growth ET sensitive breast tumor Treatment with ET + CDK4/6 inhibitor ER-dependent ER-independent resistance†,* resistance† MAPK PI3K/AKT ESR1- GF RTK pathway pathway mutation alteration alteration upregulation (40-50%
Slide 6: Vepdegestrant has potential to be a best-in-class treatment in ESR1 mutant breast cancer
Vepdegestrant has potential to be a best-in-class treatment in ESR1 mutant ER+/HER2- advanced breast cancer Novel treatment options are needed for the ~20k patientsa with ESR1-mutated ER+/HER2- advanced or metastatic breast cancer in the 2L setting In VERITAC-2, vepdegestrant demonstrated 5-month me
Slide 7: Phase 3 VERITAC-2 Results
Phase 3 VERITAC-2 Results ARVINAS
Slide 8: VERITAC-2: Global Phase 3 Clinical Trial of Vepdegestrant
VERITAC-2: Global Phase 3 Clinical Trial of Vepdegestrant Key Eligibility Criteria 28-day Treatment Cycles • Age ≥18 years old Primary Endpoints: • ER+/HER2- advanced or metastatic breast Vepdegestrant (n=313) • PFS by BICR in cancer ‒ ESR1m population Randomization (1:1) • Prior therapy: 200 mg ora
Slide 9: VERITAC-2: Patient Disposition
VERITAC-2: Patient Disposition Randomized (1:1) All patients, n=624; ESR1m, n=270 Vepdegestrant Fulvestrant All patients, n=313 All patients, n=311 ESR1m, n=136 ESR1m, n=134 Discontinued treatment Discontinued treatment Treated Treated All patients/ESR1m, n=216/90 All patients, n=312 All patients, n
Slide 10: Patient population in VERITAC-2 representative of real-world second-line setting in the U.S.
Patient population in VERITAC-2 representative of the real-world second-line setting in the U.S. Patients With ESR1m All Patients Patients With ESR1m All Patients Vepdegestrant Fulvestrant Vepdegestrant Fulvestrant Vepdegestrant Fulvestrant Vepdegestrant Fulvestrant Characteristic (n=136) (n=134) (n
Slide 11: Vepdeg met the primary endpoint with ~3-month improvement in mPFS in ESR1 mutant patients
Vepdeg met the primary endpoint with a ~3-month improvement in mPFS in patients with tumors harboring ESR1 mutations 100 Vepdegestrant Fulvestrant Vepdegestrant n=136 n=134 90 Fulvestrant Median follow-up, months 7.4 6.0 80 Events, n (%) 79 (58) 95 (71) 70 Median PFS by BICR, months 5.0 2.1 6-mont
Slide 12: Vepdeg did not meet the primary endpoint in the ITT population
Vepdeg did not meet the primary endpoint in the ITT population 100 Vepdegestrant Fulvestrant Vepdegestrant n=313 n=311 90 Fulvestrant Median follow-up, months 7.4 7.2 80 Events, n (%) 186 (59) 198 (64) 70 Median PFS by BICR, months 3.7 3.6 (95% CI) (3.6–5.3) (2.2–3.8) 60 Stratified HR (95% CI) 0.8
Slide 13: Statistically significant improvements in CBR and ORR in the ESR1 mutant population
Vepdeg showed statistically significant improvements in CBR and ORR in the ESR1 mutant population Patients With ESR1m All Patients CBRa ORRb CBRa ORRb 80 80 70 Odds ratio: 2.88 70 (95% CI: 1.57–5.39) 60 60 13 Odds ratio: 1.29 P<0.001c 42.1 (95% CI: 0.89–1.91) 50 50 P=0.16c Odds ratio: 5.45 % ± 95% C
Slide 14: Consistent PFS benefit across pre-specified subgroups in the ESR1m population
Consistent PFS benefit across pre-specified prognostic characteristics/ baseline disease demographics in the ESR1m population Events/n Subgroup Vepdegestrant Fulvestrant HR (95% CI) All patients (stratified) 79/136 95/134 0.57 (0.42–0.77) Age, years <65 50/86 66/88 0.51 (0.35–0.74) ≥65 29/50 29/46 0
Slide 15: Vepdeg generally well-tolerated, with low discontinuation and dose reduction rates
Vepdeg was generally well-tolerated, with low rates of discontinuation and dose reductions; majority of TRAEs Gr 1/2 Overview TEAEs in >10% of Patients in Either Group Vepdegestrant Fulvestrant Vepdegestrant Fulvestrant TEAEs, % (n=312) (n=307) (n = 312) (n = 307) Any grade 87 81 TEAE, % Any Grade G
Slide 16: High unmet need remains for improved treatment options in 2L+, ESR1 mutant setting
High unmet need remains for improved treatment options for patients in 2L+, ESR1 mutant setting Current treatment landscape in 2L+, ESR1 mutant mBC ~20K patients treated each year in the U.S. EFFICACY MEASURES TOLERABILITY REAL-WORLD APPLICABILITY • HCP seeking additional benefits • GI-related event
Slide 17: Vepdegestrant has the potential to be best-in-class treatment in 2L+ ESR1 mutant setting
Vepdegestrant has the potential to be best-in-class treatment in the 2L+, ESR1 mutant setting Vepdegestrant has the potential to be: BEST-IN-CLASS TREATMENT without tradeoffs between efficacy, tolerability, and patient reported outcomes EFFICACY MEASURES TOLERABILITY REAL-WORLD EXPERIENCE 2.5x ~3-mo
Slide 18: Positive VERITAC-2 results support potential regulatory filings
Positive results from VERITAC-2 Phase 3 clinical trial support a potential regulatory filings Vepdegestrant is the first PROTAC degrader to demonstrate clinical benefit in a Phase 3 trial Potential to address high unmet need for patients with tumors harboring an ESR1 mutation in 2L+ setting Vepdeg s
Slide 19: Impactful near-term milestones across Arvinas' clinical portfolio
Impactful near-term milestones across Arvinas’ clinical portfolio Program Anticipated Milestone Timing Potential Impact Vepdeg with Submit NDA 2H 2025 Rapid progress towards potential commercialization in 2026 Data from Ph 1 SAD cohort Potential to show biomarkers changes and degradation in PD ARV-1
Slide 20: Igniting a transformative change
IGNITING A TRANSFORMATIVE CHANGE in the fight for patients with cancer and neurodegenerative diseases